AC
CTMX icon

Athanor Capital’s CytomX Therapeutics CTMX Stock Holding History

Athanor Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,058
Closed -$177K – 862
2020
Q4 		$177K Buy
27,058
+632
+2% +$4.51K ﹤0.01% 672
2020
Q3 		$176K Sell
26,426
-20,287
-43% -$150K 0.01% 503
2020
Q2 		$389K Buy
+46,713
New +$434K 0.02% 353

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Athanor Capital's CTMX Position: Q1 2021 in Review

Athanor Capital sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 27,058 shares — an estimated $177K sold.

Athanor Capital first reported a position in CTMX in Q2 2020 and held it in 3 quarters. The position peaked at $389K in Q2 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

  • Athanor Capital reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 27,058 CytomX Therapeutics shares in Q1 2021, an estimated $177K.
  • Athanor Capital first reported a position in CytomX Therapeutics in Q2 2020 and held it in 3 quarters.
  • Athanor Capital's CytomX Therapeutics position peaked at $389K in Q2 2020.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.